Company / PP&E (Net)
AGIOS PHARMACEUTICALS, INC. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$10.8M
FY2025
5-year range
$10.8M / $28.9M
FY2021-FY2025
Trend
-7.7%
vs FY2024
Sector context
#94 of 193
Health Care
What the data says
At $11M, AGIOS PHARMACEUTICALS, INC.'s pp&e (net) ranks #94 of 193 in the Health Care sector. PP&E (Net) has declined for 5 consecutive years, from $32M in FY2020 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -19.7%.
Declined from $15M to $11M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -22.3%
- 5-Year CAGR
- -19.7%
- 10-Year CAGR
- -
Sector benchmark
#94 of 193 in Health CareTop 49% of 193This company $10.8M Sector average $777.6M
▼
-98.6% below sector average
Key checks
Key Insights
- AGIOS PHARMACEUTICALS, INC.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -19.7%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 7.7% year-over-year.
- Ranks #94 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.8M | -7.7% |
| FY2024 | $11.7M | -24.1% |
| FY2023 | $15.4M | -33.1% |
| FY2022 | $23.0M | -20.5% |
| FY2021 | $28.9M | -10.4% |
| FY2020 | $32.3M | +2.6% |
| FY2019 | $31.5M | +29.4% |
| FY2018 | $24.3M | -0.5% |
| FY2017 | $24.4M | -3.6% |
| FY2016 | $25.3M | +9.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026